Glioblastoma is a primary malignant brain tumor with a poor prognosis. An effective treatment for glioblastoma is needed. Magnolol is a natural compound from Magnolia officinalis suggested to have antiproliferative activity. The aim of this research was to investigate the anticancer effects of magnolol in glioma, with an emphasis on migration and the underlying mechanism. Magnolol decreased the expression of focal adhesion-related proteins and inhibited LN229 and U87MG glioma cell migration. The levels of phosphorylated myosin light chain (p-MLC), phosphorylated myosin light chain kinase and myosin phosphatase target subunit 1 were reduced in response to magnolol treatment. In addition, immunostaining and membrane fractionation showed that the distribution of N-cadherin at the glioma cell membrane was decreased by magnolol. In an orthotropic xenograft animal model, magnolol treatment not only inhibited tumor progression but also reduced p-MLC and N-cadherin protein expression. In conclusion, magnolol reduces cell migration, potentially through regulating focal adhesions and N-cadherin in glioma cells. Magnolol is a potential candidate for glioma treatment.
INTRODUCTION
Glioblastomas (GBMs) are primary intracranial tumors in the brain and CNS (1) . GBMs are characterized by poorly differentiated neoplastic astrocytes that have high proliferative and invasive abilities (2) . Although there are clinical treatment modalities for GBM, the 5-year survival rate of patients with GBM remains poor (3) . It is difficult to identify prognostic factors that are correlated with GBM; over 95% of GBM patients die within 3 months after diagnosis without therapy (4) . In human brain cancer, high-grade glioma cells often actively migrate through the extracellular space within the brain; moreover, motility pathways become dysregulated, further increasing the migratory behavior of GBM cells (5) . In glioma, rapid invasion and migration are important factors in tumor progression. The modulation of focal adhesions, cell junctions, and the cytoskeleton is involved in cancer cell migration (6) . Therefore, the identification of drugs for adjuvant therapy to improve the efficacy of surgery and chemotherapy is an extremely important task for GBM treatment.
Magnolol, extracted from the root and stem bark of Magnolia officinalis, is commonly used as a traditional herbal medicine in East Asia. A previous study showed that magnolol induces apoptosis and impedes cell proliferation by promoting cell cycle arrest and upregulates the expression of proapoptotic molecules in human GBM cells (7) . Magnolol interferes with the cell cycle by increasing p27/kip1 and p21/Cip1 expression in U373 glioma cells (8) . Additionally, magnolol has been reported to inhibit the migration of vascular smooth muscle cells through phosphorylation of focal adhesion kinase (FAK) (9) . In human prostate cancer, magnolol inhibits PC3 cell migration/invasion by downregulating the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 (10) . However, the effect of magnolol on glioma cell migration has not been elucidated. Therefore, we hypothesized that magnolol may inhibit GBM tumor cell migration and invasion. The aim of this study was to investigate the anticancer effects of magnolol in glioma, with a focus on cell migration and its underlying mechanism. Migration-related proteins, including the focal adhesion complex, myosin light chain (MLC), MLC kinase (MLCK), and Ncadherin/b-catenin, were investigated after human GBM cells were treated with magnolol.
MATERIALS AND METHODS
All in vivo studies were approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center.
Cell Culture
Two human GBM cell lines, U87MG and LN229, were purchased from American Type Culture Collection (ATCC, Rockville, MD). LN229-Luc2 cells were generated via stable transfection of LN229 cells with pLuc2-iRFP and selection using a FACS Aria Fusion Sorter (BD Biosciences, Franklin Lakes, NJ). Cells were grown in Dulbecco's modified Eagle's medium ([DMEM], Gibco BRL, Grand Island, NY) containing 10% fetal bovine serum, 100 IU/mL penicillin, and streptomycin (Gibco BRL) in a humidified atmosphere of 5% CO 2 at 37 C.
Cell Survival Assay
U87MG and LN229 cells were seeded in 96-well plates at 5 Â 10 3 cells/well. Cells were treated with magnolol (Sigma-Aldrich, St. Louis, MO) at different concentrations (0.5-60 lM) for 24 hours and then washed with phosphatebuffered saline (PBS), pH 7.4 (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH 2 PO 4 , 8 mM Na 2 HPO 4 ). Cells were incubated with 0.5 mg/mL 2, 3, 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) for 4 hours and then lysed with DMSO, and the absorbance was measured at 590 nm.
Wound Healing Assay
Cells were cultured to confluence, and a scratch was then created using a 200-lL pipette tip. Cells were washed twice with PBS and then treated with 40 or 60 lM magnolol for 16 hours (U87MG cells) and 24 hours (LN229 cells). Cell images from 3 independent experiments were captured and analyzed using ImageJ.
Cell Migration Transwell Assay
Transwell migration assays were performed by seeding 2 Â 10 4 U87MG and LN229 GBM cells in the upper chamber of a Transwell chamber (Costar, Acton, MA). Cells were subsequently incubated with magnolol at various concentrations for 24 hours. Cells were washed with PBS, fixed with formalin for 10 minutes, and stained with Coomassie Brilliant Blue G250 (Sigma-Aldrich). Cells in the upper chamber were removed with a cotton swab after incubation. All invaded cells were counted by ImageJ. The results are presented as the average of 9 random fields from each membrane from 9 individual experiments.
Western Blotting
After treatment, GBM cells were washed with PBS and homogenized in lysis buffer (0.15% Triton X-100, 10 mM EGTA, 2 mM MgCl 2 , 60 mM PIPES, 2.5 mM HEPES, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 1 lg/ mL leupeptin, 1 lg/mL pepstatin A, 1 mM Na 4 VO 3 ). Protein samples were separated by SDS-polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (Bio-Rad Life Science, Hercules, CA). The blots were blocked with 5% nonfat milk in TBS-Tween (150 mM NaCl, 50 mM Tris-base, 0.1% Tween-20, pH 7.4) and then incubated for >16 hours with a 1:500 dilution of primary antibodies against p-FAK (8556), p-paxillin (2541), p-Src (6943), integrin b3 (13166), integrin b1 (34971), and myosin phosphatase target subunit 1 (MYPT1, 8574) (Cell Signaling Technology, Danvers, MA); FAK (610088) and paxillin (610051) (BD Biosciences); p-MLC (ab2480), MLC (ab92721), Src (ab109381), MLCK (ab76092), and p-MLCK (ab200809, Abcam, Cambridge, UK); and p-MYPT1 (ABS45, Merck Millipore, Darmstadt, Germany). Other blots were incubated with a 1:1000 dilution of primary antibodies against GAPDH (ab181602, Abcam); and N-cadherin (610920), E-cadherin (610181) and b-catenin (610154) (BD Biosciences). Then, HRP-conjugated antimouse (ab6728) or antirabbit (ab6721) IgG secondary antibodies (Abcam, Cambridge, MA) were applied. All the blots were developed in an ECL substrate-developing solution (Bio-Rad Life Science) to produce chemiluminescence images, which were measured by UVP Biospectrum AC. The band densities were quantified by Gel-Pro version 3.1 (Media Cybernetics, Silver Spring, MD), and the density of target bands was normalized to that of control bands. Phosphorylated protein levels were normalized to total protein levels.
Membrane Protein Fractionation
GBM cells were incubated with 20 lM, 40 lM, or 60 lM magnolol. After 24 hours, membrane proteins were extracted using the Native Membrane Protein Extraction Kit (Calbiochem, Merck Millipore, Darmstadt, Germany). The resulting supernatants were assayed by SDS gel electrophoresis using a nonreducing SDS sample buffer. Then, the membrane expression of N-cadherin (610920, 1:1000, BD Biosciences), b-catenin (610154, 1:1000, BD Biosciences), and Na þ /K þ ATPase (ab76020, 1:1000, Abcam) was analyzed by Western blotting.
Immunofluorescence GBM cells were seeded and cultured on slides. Magnolol was added at various concentrations for 24 hours. Cells were fixed with fixing buffer (PBS with 10% formaldehyde, 4% sucrose, 0.15 mM CaCl 2 ), incubated with permeabilization buffer (PBS with 0.2% Triton X-100) and blocked with blocking buffer (PBST with 5% nonfat milk). A primary antibody against N-cadherin (1:200 dilution) was incubated with the samples for >16 hours at 4 C. Secondary antibodies and DAPI (D1306, Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA) were incubated with the samples, which were sealed to avoid light after the PBST washing procedure. Images were taken using a cooled CCD camera.
Immunoprecipitation
Cells were incubated with magnolol for 24 hours and then lysed on ice for 15 minutes with RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 50 mM NaF). Cell lysates were centrifuged at 12 000 g for 15 minutes. The proteins were mixed with b-catenin antibody at a ratio of 400:1 lg. The Protein A Mag Sepharose Xtra (GE Healthcare) bead purification procedures were followed, and the samples were then evaluated by SDS-polyacrylamide gel electrophoresis. The protein expression of N-cadherin (610920, 1:1000, BD Biosciences), b-catenin (610154, 1:1000, BD Biosciences), and IgG heavy chain (ab6789, 1:100, Abcam) was analyzed by Western blotting.
Animal Xenograft Model
BALB/cAnN.Cg-Foxn1nu/CrlNarl nude mice (20-25 g) were anesthetized with an O 2 /isoflurane mixture, and 10 5 LN229-Luc2 cells were implanted in the right cerebral hemisphere. Two days after implantation, the animals were allocated randomly into 2 groups, namely, the placebo and the magnolol groups (n ¼ 5), which received 0.9% NaCl or magnolol (20 mg/kg/day) by intraperitoneal injection for 10 days. Body weight was measured every 3 days throughout the experiment. The bioluminescence intensity of the implanted tumors was measured 3 times per mouse using the noninvasive In Vivo Imaging System (IVIS). The substrate luciferin was used by luciferase to produce luminescence in LN229-Luc2 cells to identify the location and growth status of cancer cells. Ten minutes after the intraperitoneal injection of luciferin, the head of each mouse was fixed on the bed frame of the IVIS, and the mouse brain was adjusted to the center of the camera's FOV (field of view) to capture a dynamic image. The images were analyzed using Living Image 250 software. Mice were killed after 10 days.
Histology and Immunohistochemistry
Orthotopic tumors were harvested, rinsed twice with PBS and fixed in 4% paraformaldehyde. Tissues were paraffin embedded and sliced into 5-lm-thick sections. After dewaxing, histological evaluation was performed by hematoxylin and eosin (H&E) staining. Expression of p-MLC and N-cadherin in brain tumors of nude mice was determined using immunohistochemistry after antigen retrieval with primary antibodies against p-MLC (Abcam, 1:200) and N-cadherin (BD Biosciences, 1:200) and secondary goat antirabbit (111-035-003) or antimouse (115-035-003) antibodies (Jackson Laboratories, Bar Harbor, ME). The expression of p-MLC and N-cadherin was analyzed based on images from 3 random fields in each group.
Statistical Analysis
All in vitro experiments were performed at least 6 times, and the results are presented as the mean 6 SD of all experiments. The results of animal experiments are presented as the mean 6 SEM. Differences between means were assessed by the Kruskal-Wallis test. The Mann-Whitney test was used for postanalysis. Statistical significance was set at p < 0.05. The statistical analysis was performed by GraphPad Prism.
RESULTS

Magnolol Reduces Human GBM Cell Migration
To evaluate the toxicity of magnolol in human GBM cells, the survival rates of LN229 and U87MG cells treated with magnolol were analyzed. The viability of LN229 and U87MG cells after treatment with 60 lM magnolol was comparable (Fig. 1A) . However, migration was significantly reduced in LN229 cells treated with 20 lM magnolol (p ¼ 0.003) and in U87MG cells treated with 40 lM magnolol (p ¼ 0.0035), as determined by wound healing assay (Fig. 1B,  C) . In the transwell migration assay, a significant decrease in migration was observed in LN229 and U87MG cells treated with 20 lM magnolol (p ¼ 0.0001) (Fig. 2A, B) .
Magnolol Decreases the Activity of the Focal Adhesion Complex and MLC
Magnolol at 60 lM reduced the levels of p-FAK (p ¼ 0.0079), p-paxillin (p ¼ 0.0079), and p-Src (p ¼ 0.0003) by 32%, 21.9%, and 20.2%, respectively, in LN229 cells (Fig. 3A) . In addition, the expression of integrin b1 (p ¼ 0.0065) and integrin b3 (p ¼ 0.0154) was downregulated by magnolol (Fig. 3A) . These results indicated that magnolol may interfere with focal adhesion complex formation in GBM cells. Moreover, p-MLC, p-MLCK, and p-MYPT levels were decreased by magnolol (Fig. 3B) . These results suggested that the reduction in MLC phosphorylation may stem from the decreases in MLCK and MYPT1 phosphorylation, which then interferes with the formation of stress fibers.
Magnolol Reduces N-Cadherin Expression in GBM Cells
Magnolol treatment significantly inhibited N-cadherin expression at concentrations of 40 lM and 60 lM (p ¼ 0.026 and 0.0008), whereas there was no effect on the protein expression levels of b-catenin and E-cadherin (Fig. 4A ). By contrast, membrane levels of N-cadherin and b-catenin were reduced in response to 40 lM (p¼ 0.0062) and 20 lM (p ¼ 0.008) magnolol, respectively (Figs. 4B, 5) . In addition, the interaction between N-cadherin and b-catenin was increased in the presence of magnolol (Fig. 4C) . These results showed that magnolol reduces N-cadherin expression and increases the interaction between N-cadherin and b-catenin, which may inhibit the migration of human GBM cells.
Effects of Magnolol on Tumor Progression in an Orthotropic Human GBM Xenograft Mouse Model
Human LN229 GBM cells expressing luciferase were implanted into nude mice. Glioma progression was measured based on the bioluminescence imaging (BLI) value determined by the IVIS. Treatment with 20 mg/kg magnolol for 10 days caused a significant tumor regression compared with placebo (ratio of the BLI value in the placebo group to that in the magnolol group ¼ 55.5:1; p ¼ 0.0079; n ¼ 5 per group; Fig. 6A, B) . There was no significant difference in body weight loss between the 2 groups (Fig. 6C) . However, the final body weight in both groups was reduced significantly compared with that at day 0 (Fig. 6C , p ¼ 0.015 and 0.017 to the placebo and magnolol treatment, respectively). H&E staining also showed the reduction in tumor size in the magnolol group (Fig. 6D) . Moreover, N-cadherin and p-MLC expression levels were inhibited by magnolol (Fig. 6D) . These results revealed that N-cadherin and p-MLC expression levels may be involved in the magnolol-induced reduction of tumor migration and progression in vivo (Fig. 6D, E) .
DISCUSSION
Brain cancer rarely metastasizes to other organs and tissues (11), but high-grade glioma cells often actively migrate through the extracellular space within the brain (12, 13) . Although tumor growth seemed like a solid mass in Figure 6 , there were still tumor cells migrating out of the mass at the margin area. However, a single tumor cell migration was not easily observed in the orthotopic animal model. The increased motility of glioma cells causes GBM to be highly migratory (5) . In a previous study, we demonstrated that magnolol reduces cell proliferation and induces apoptosis in human GBM cells (7) . The survival rate of LN229 and U87MG glioma cells was not significantly different after treatment with 60 lM magnolol compared with control.
Magnolol has been reported to inhibit cell migration and to induce apoptosis in several types of cancer cells. Magnolol induces cell cycle arrest through p53 in human gallbladder cancer cells (14) and causes caspase-independent apoptosis in nonsmall cell lung cancer cells (15) . In MDA-MB-231 breast cancer cells, magnolol inhibits migration through attenuating FAK phosphorylation and the interaction between p-FAK and p-paxillin (16) . FAK, which is part of the focal adhesion complex, is a tyrosine kinase that controls focal adhesion stability and other cellular functions, including migration, invasion, metastasis, survival, and proliferation (17) . During tumor cell migration, FAK cooperates with paxillin, integrin, and Src proteins to drive focal adhesion complex formation and to coordinate cell motility (18, 19) . Magnolol suppresses invasion and migration by reducing MMP-2 and MMP-9 levels in human PC-3 prostate carcinoma cells (10) . Herein, the data suggested that magnolol exerts antimigratory effects potentially through focal adhesion inhibition, cytoskeleton remodeling, and cadherin/catenin redistribution in human GBM cells. N-cadherin is critical for maintaining the junctional structure and is involved in glioma cell migration (20, 21) . Upregulation of N-cadherin in malignant glioma leads to increased cell migration and abnormal adhesion motile behavior (22) . Knockdown of adenylated cyclase-associated protein 1 decreases N-cadherin expression but increases E-cadherin expression, which inhibits glioma cell metastasis (20) . Impairment of the cadherin-mediated cell junction is required to promote migration in T98G and U373MG GBM cells (23) . bCatenin is a subunit of the cadherin protein complex, is involved in the coordination of cell-cell adhesion, and acts as a signal transduction molecule in the Wnt signaling pathway (24) (25) (26) . In glioma cells, active b-catenin may further promote invasion and migration (27) . Suppression of the Wnt/b-catenin signaling pathway inhibits LN229 and U87 glioma cell proliferation and invasion (28, 29) . Although E-cadherin and b-catenin expression in human glioma cells was unaffected by magnolol, N-cadherin expression and membrane-bound levels were decreased, which may impair the stability of adherens junctions and reduce the migration of glioma cells.
The N-cadherin/b-catenin complex plays an important role in cancer cell migration; formation of this complex blocks human glioma cell migration and invasion by inhibiting Fynrelated kinase (30) . During the transendothelial migration of melanoma cells, tyrosine phosphorylation of N-cadherin is increased, leading to the dissociation of b-catenin from regions of cell-cell contact (31) . Tyrosine phosphorylation of N-cadherin may reduce the binding of b-catenin in GBM cells. However, the phosphorylation status of N-cadherin after magnolol treatment of glioma cells must be further studied. Magnolol reduced N-cadherin expression and increased the interaction between N-cadherin and b-catenin, supporting the decrease in LN229 cell migration. However, the underlying mechanism by which magnolol increases the interaction between Ncadherin/b-catenin still needs further investigation.
MLC dephosphorylation impairs stress fiber formation and reduces the migration of human glioma cells (32) . ROCK activation contributes to the phosphorylation of MYPT1 and MLC, which increases endometrial stromal cell migration (33) . Magnolol inhibits migration via dephosphorylation of MLC and FAK and cytoskeleton remodeling in vascular smooth muscle cells (9) . Moreover, MLC and MYPT1 phosphorylation levels were decreased after magnolol treatment, leading to a reduction of vascular tension (34) . Reductions in MLCK disrupt peripheral actin stress fibers, possibly leading to the inhibition of glioma cell migration (35) (36) (37) . In aortic smooth muscle cells, magnolol reduces MLC phosphorylation and RhoA/Cdc42 activation to inhibit the formation of stress fibers (9, 34) . In this study, magnolol decreased MLC and MLCK phosphorylation, which may impair cytoskeleton remodeling, subsequently inhibiting LN229 glioma cell migration. MYPT1 may not be the primary contributor to MLC dephosphorylation after treatment with 60 lM magnolol. Moreover, whether magnolol inhibits ROCK activity requires further investigation. In summary, magnolol reduced human GBM cell migration by decreasing the expression of focal adhesion-related proteins such as p-MLC, p-MLCK, and Ncadherin, potentially providing a new therapeutic strategy for glioma treatment in the future.
